Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: Outcomes following randomized switch to either duloxetine or escitalopram

Journal of Psychiatric Research

Volumn 46, Issue 5, 2012, Pages 667-674

  Raskin, Joel ^a   George, Thomas ^b   Granger, Renee E ^c   Hussain, Nadia ^a   Zhao, George Weizhong ^c   Marangell, Lauren B ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b North West Specialist Centre ^*  (Australia)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Apathy; Duloxetine hydrochloride; Escitalopram; Major depressive disorder; Norepinephrine; Serotonin

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY; APATHY; APATHY EVALUATION SCALE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART RATE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; APATHY; CITALOPRAM; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859872874     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.02.010     Document Type: Article

References (27)

1. Barnhart W.J., Makela E.H., Latocha M.J. SSRI-induced apathy syndrome: a clinical review. Journal of Psychiatric Practice 2004, 10:196-199.
2. Birkmayer W., Riederer P. Understanding the neurotransmitters: keys to the workings of the brain 1989, Blau K, trans., Springer-Verlag Wien, New York, NY.
3. Bolling M.Y., Kohlenberg R.J. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychotherapy and Psychosomatics 2004, 73:380-385.
4. Demyttenaere K., Jaspers L. Review: bupropion and SSRI-induced side effects. Journal of Psychopharmacology 2008, 22:792-804.
5. Fava M., Graves L.M., Benazzi F., Scalia M.J., Iosifescu D.V., Alpert J.E., et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. Journal of Clinical Psychiatry 2006, 67:1754-1759.
6. Fava M., Iosifescu D.V., Pedrelli P., Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychotherapy and Psychosomatics 2009, 78:91-97.
7. Gahimer J., Wernicke J., Yalcin I., Ossanna M.J., Wulster-Radcliffe M., Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Current Medical Research and Opinion 2007, 23:175-184.
8. Garland E.J., Baerg E.A. A motivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2001, 11:181-186.
9. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysical analysis in the rat. Synapse 2000, 36:205-221.
10. Gold P.W., Chrousos G.P. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proceedings of the Association of American Physicians 1999, 111:22-34.
11. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976, DHEW Publication ADM-76-338, US Department of Health, Education, and Welfare, Rockville (MD).
12. Hoehn-Saric R., Lipsey J.R., McLeod D.R. Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology 1990, 10:343-345.
13. Hoehn-Saric R., Harris G.J., Pearlson G.D., Cox C.S., Machlin S.R., Camargo E.E. A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. Journal of Clinical Psychiatry 1991, 52:131-133.
14. Hudson J.I., Wohlreich M.M., Kajdasz D.K., Mallinckrodt C.H., Watkin J.G., Martynov O.V. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharmacology 2005, 20:327-341.
15. Marangell L.B., Johnson C.R., Kertz B., Zboyan H.A., Martinez J.M. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible dose study. Journal of Clinical Psychiatry 2002, 63:391-395.
16. Marin R.S., Biedrzycki R.C., Firinciogullari S. Reliability and validity of the apathy evaluation scale. Psychiatry Research 1991, 38:143-162.
17. McClintock S.M., Husain M.M., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Trivedi M.H., et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Journal of Clinical Psychopharmacology 2011, 31:180-186.
18. Montgomery S.A., åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979, 134:382-389.
19. Norman T.R., Olver J.S. Continuation treatment of major depressive disorder: is there a case for duloxetine?. Journal of Drug Design, Development and Therapy 2010, 4:19-31.
20. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine 1995, 25:1171-1180.
21. Posternak M.A., Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. Journal of Clinical Psychiatry 2005, 66:705-707.
22. Rothschild A.J. The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity. Comprehensive Psychiatry 2008, 49:508-513.
23. Segal M. Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. Journal of Physiology 1979, 286:401-415.
24. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl. 20):22-33.
25. Stahl S.M., Grady M.M., Moret C., Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums 2005, 10:732-747.
26. Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C., Detke M.J. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. Journal of Clinical Psychopharmacology 2005, 25:132-140.
27. Wongpakaran N., van Reekum R., Wongpakaran T., Clarke D. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Annals of General Psychiatry 2007, 6:7.